Tags

Type your tag names separated by a space and hit enter

Disease-related autoantibody profile in patients with systemic sclerosis.
Autoimmunity. 2017 Nov; 50(7):414-421.A

Abstract

BACKGROUND

Autoantibodies (autoAbs) help in diagnosis and predicting clinical phenotypes in systemic sclerosis (SSc).

AIM OF THE STUDY

To determine the clinical utility of 13 SSc-related autoAbs in SSc patients.

MATERIAL AND METHODS

A total of 131 consecutive patients with SSc (111 female, mean age 58.1 ± 14 years; 49 with diffused cutaneous SSc [dcSSc] and 82 with limited cutaneous SSc [lcSSc]) were analysed by a multiplex line immunoassay (Euroimmun) for autoantibodies (autoAbs) against 13 SSc-related antigens. A total of 22 patients with primary Raynaud phenomenon (RP), and 22 healthy controls were also analysed.

RESULTS

ANA by indirect immunofluorescence was present in 128 (97.7%) patients with SSc. Excluding anti-Ro52, 113 (89.3%) SSc patients were positive for at least one autoAb: anti-Topoisomerase I (anti-Topo) I abs in 54 (41.2%), anti-centromere proteins (anti-CENP) in 37 (28.2%, all reactive with centromere protein-A (CENPA) and centromere protein B (CENPB)), anti-RNA polymerase III(RP11) in 19 (14.5%), anti-RNA polymerase III(RP155) in 13 (9.9%), anti-fibrillarin in 4 (3.1%), anti-Ku in 6 (4.6%), anti-nucleolus-organizing region (anti-NOR90) in 8 (6.1%), anti-PM-Scl100 in 2 (1.5%), and anti-PM-Scl75 in 4 (3.1%). There was no immunoreactivity for Th/To or platelet-derived growth factor receptor (PDGFR). Overall, 102 (77.9%) SSc patients had autoAbs against Topo I, CENPA or CENPB, RP11 or RP155. Anti-Topo I abs were strongly associated with dcSSc, interstitial lung disease (ILD) (p < .001), pulmonary hypertension (PH) (p = .019) and ILD-PH (p = .003). Anti-CENPB abs were associated with lcSSc, and negatively associated with ILD. Anti-RP11 and anti-NOR90 abs were associated with male gender, and anti-NOR90 associated with ILD.

CONCLUSIONS

Anti-Topo I, anti-CENP, and anti-RNA pol III are the most prevalent autoAbs in SSc. Anti-Topo I and anti-NOR90 abs are associated with ILD and/or PAH.

Authors+Show Affiliations

a Department of Rheumatology and Clinical Immunology , Faculty of Medicine, School of Health Sciences, University of Thessaly , Larissa , Greece.a Department of Rheumatology and Clinical Immunology , Faculty of Medicine, School of Health Sciences, University of Thessaly , Larissa , Greece. b Biomedical Section , Institute of Research and Technology Thessaly, Centre for Research and Technology Hellas (CERTH) , Larissa , Greece.a Department of Rheumatology and Clinical Immunology , Faculty of Medicine, School of Health Sciences, University of Thessaly , Larissa , Greece.a Department of Rheumatology and Clinical Immunology , Faculty of Medicine, School of Health Sciences, University of Thessaly , Larissa , Greece. b Biomedical Section , Institute of Research and Technology Thessaly, Centre for Research and Technology Hellas (CERTH) , Larissa , Greece.a Department of Rheumatology and Clinical Immunology , Faculty of Medicine, School of Health Sciences, University of Thessaly , Larissa , Greece. b Biomedical Section , Institute of Research and Technology Thessaly, Centre for Research and Technology Hellas (CERTH) , Larissa , Greece.c Institute of Immunology affiliated to Euroimmun AG , Lübeck , Germany.c Institute of Immunology affiliated to Euroimmun AG , Lübeck , Germany.a Department of Rheumatology and Clinical Immunology , Faculty of Medicine, School of Health Sciences, University of Thessaly , Larissa , Greece. b Biomedical Section , Institute of Research and Technology Thessaly, Centre for Research and Technology Hellas (CERTH) , Larissa , Greece. d Division of Transplantation, Immunology and Mucosal Biology , MRC Centre for Transplantation, King's College London Medical School , London , UK.a Department of Rheumatology and Clinical Immunology , Faculty of Medicine, School of Health Sciences, University of Thessaly , Larissa , Greece. e Center for Molecular Medicine , Old Dominion University , Norfolk , VA , USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28749191

Citation

Liaskos, Christos, et al. "Disease-related Autoantibody Profile in Patients With Systemic Sclerosis." Autoimmunity, vol. 50, no. 7, 2017, pp. 414-421.
Liaskos C, Marou E, Simopoulou T, et al. Disease-related autoantibody profile in patients with systemic sclerosis. Autoimmunity. 2017;50(7):414-421.
Liaskos, C., Marou, E., Simopoulou, T., Barmakoudi, M., Efthymiou, G., Scheper, T., Meyer, W., Bogdanos, D. P., & Sakkas, L. I. (2017). Disease-related autoantibody profile in patients with systemic sclerosis. Autoimmunity, 50(7), 414-421. https://doi.org/10.1080/08916934.2017.1357699
Liaskos C, et al. Disease-related Autoantibody Profile in Patients With Systemic Sclerosis. Autoimmunity. 2017;50(7):414-421. PubMed PMID: 28749191.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Disease-related autoantibody profile in patients with systemic sclerosis. AU - Liaskos,Christos, AU - Marou,Emmanouela, AU - Simopoulou,Theodora, AU - Barmakoudi,Maria, AU - Efthymiou,Georgios, AU - Scheper,Thomas, AU - Meyer,Wolfgang, AU - Bogdanos,Dimitrios P, AU - Sakkas,Lazaros I, Y1 - 2017/07/27/ PY - 2017/7/28/pubmed PY - 2018/6/7/medline PY - 2017/7/28/entrez KW - Autoimmunity KW - autoantibodies KW - fibrosis KW - line assay KW - scleroderma KW - ulcers SP - 414 EP - 421 JF - Autoimmunity JO - Autoimmunity VL - 50 IS - 7 N2 - BACKGROUND: Autoantibodies (autoAbs) help in diagnosis and predicting clinical phenotypes in systemic sclerosis (SSc). AIM OF THE STUDY: To determine the clinical utility of 13 SSc-related autoAbs in SSc patients. MATERIAL AND METHODS: A total of 131 consecutive patients with SSc (111 female, mean age 58.1 ± 14 years; 49 with diffused cutaneous SSc [dcSSc] and 82 with limited cutaneous SSc [lcSSc]) were analysed by a multiplex line immunoassay (Euroimmun) for autoantibodies (autoAbs) against 13 SSc-related antigens. A total of 22 patients with primary Raynaud phenomenon (RP), and 22 healthy controls were also analysed. RESULTS: ANA by indirect immunofluorescence was present in 128 (97.7%) patients with SSc. Excluding anti-Ro52, 113 (89.3%) SSc patients were positive for at least one autoAb: anti-Topoisomerase I (anti-Topo) I abs in 54 (41.2%), anti-centromere proteins (anti-CENP) in 37 (28.2%, all reactive with centromere protein-A (CENPA) and centromere protein B (CENPB)), anti-RNA polymerase III(RP11) in 19 (14.5%), anti-RNA polymerase III(RP155) in 13 (9.9%), anti-fibrillarin in 4 (3.1%), anti-Ku in 6 (4.6%), anti-nucleolus-organizing region (anti-NOR90) in 8 (6.1%), anti-PM-Scl100 in 2 (1.5%), and anti-PM-Scl75 in 4 (3.1%). There was no immunoreactivity for Th/To or platelet-derived growth factor receptor (PDGFR). Overall, 102 (77.9%) SSc patients had autoAbs against Topo I, CENPA or CENPB, RP11 or RP155. Anti-Topo I abs were strongly associated with dcSSc, interstitial lung disease (ILD) (p < .001), pulmonary hypertension (PH) (p = .019) and ILD-PH (p = .003). Anti-CENPB abs were associated with lcSSc, and negatively associated with ILD. Anti-RP11 and anti-NOR90 abs were associated with male gender, and anti-NOR90 associated with ILD. CONCLUSIONS: Anti-Topo I, anti-CENP, and anti-RNA pol III are the most prevalent autoAbs in SSc. Anti-Topo I and anti-NOR90 abs are associated with ILD and/or PAH. SN - 1607-842X UR - https://www.unboundmedicine.com/medline/citation/28749191/Disease_related_autoantibody_profile_in_patients_with_systemic_sclerosis_ L2 - https://www.tandfonline.com/doi/full/10.1080/08916934.2017.1357699 DB - PRIME DP - Unbound Medicine ER -